Drug Approval | July 03, 2022
Pfizer submits new drug application to the U.S. FDA for Paxlovid
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
It is a two dose vaccine to be administered intramuscularly at 28 days apart
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
The Congress was held on June, 20-21, 2022 in Berlin, Germany
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Subscribe To Our Newsletter & Stay Updated
